G.P. KAPADIA & CO
Chartered Accountants

Hamam House
Ambalal Doshi Marg,
Mumbai - 400 001

Tel. : 2265 4239, 2265 4313
E-mail- : gpkco@yahoo.com

Limited Review Report on the Unaudited Consolidated Financial Results of Unihealth Hospitals Limited (Formerly Known as Unihealth Consultancy Limited) for the half year ended 30th September, 2025 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

To,
The Board of Directors
Unihealth Hospitals Limited
(Formerly Known as Unihealth Consultancy Limited)

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unihealth Hospitals Limited** (the "Holding Company')*(Formerly Known as Unihealth Consultancy Limited)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") 'and its associates for the half year ended September 30, 2025("the Statement") .The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulation, 2015"). The Statement is the responsibility of the Holding Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Aryavarta FZE	Wholly owned Subsidiary
Unihealth Pharmaceuticals Private Limited	Wholly owned Subsidiary
Unihealth Holdings Limited	Wholly owned Subsidiary
UMC Hospitals Private Limited	Subsidiary
Biohealth Limited	Subsidiary
Unihealth Tanzania Limited	Subsidiary
UMC Global Health Limited	Subsidiary
Victoria Hospitals Limited	Subsidiary
UHS Oncology Private Limited	Associate
Unihealth Uganda Limited	Associate

5. The Statement includes the results of the following entities.

(i) Two subsidiaries, whose results reflect total assets of Rs. 17813.34 lakhs as at 30th September 2025, total revenues of Rs.6331.64 lakhs and net cash inflow of Rs 523.72 lakhs for the half year period ended on that date, as considered in the unaudited consolidated financial results, out of which one subsidiary whose result reflect total assets of Rs 15402.11 lakhs as at 30th September 2025, total revenues of Rs.6324.31 lakhs and net cash inflow of Rs 510.59 lakhs for the half year period ended on that date year ended on that date, have been audited by other independent auditors and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of that subsidiary company is based solely on the financial result of subsidiary referred aforesaid.

(ii) We did not review the interim financial results of Six Subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect unaudited total assets of Rs.2343.66 lakhs and cash flows of Rs.112.21 lakhs as at 30th September 2025, unaudited total revenue from operations of Rs. 333.67 lakhs for the period ended 30 September 2025 and profit from Two Associates of Rs.28.89 lakhs, as considered in the unaudited consolidated financial results. These financial results have been prepared by the management and provided to us duly certified and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of those Subsidiary companies and Associate is based solely on the financial result of the subsidiaries and associate as referred aforesaid.

Our conclusion on the Statement is not modified in respect of the above matters.

6. Based on our review conducted and procedures performed as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the Statement has been prepared in all material respects in accordance with the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai

Digitally signed by Atul Babubhai Desai
Date: 2025.11.14 18:15:14 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 14th November, 2025
UDIN: 25030850BMGYJI6469

UNIHEALTH HOSPITAL LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR PERIOD ENDED 30TH SEPTEMBER 2025

(Rs. In lakhs)

	PARTICULARS	HALF YEAR ENDED			YEAR ENDED
		30.09.2025	31.03.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited
I	Revenue from operations	6,666.62	5,579.77	4,327.29	9,907.06
II	Other income	289.80	115.01	156.74	271.75
III	Total revenue (I + II)	6,956.42	5,694.78	4,484.03	10,178.81
IV	Expenses				
-	Purchases of stock in trade	1,246.88	1,280.29	833.47	2,113.76
-	Changes in inventories of Finished goods, Work in progress and Stock-in- trade	73.50	(67.45)	45.71	(21.74)
-	Employee benefits expense	787.15	738.32	694.97	1,433.29
-	Finance costs	118.31	123.75	191.28	315.03
-	Depreciation and amortization expense	384.64	364.61	230.66	595.27
-	Other expenses	1,387.22	1,487.28	1,221.77	2,709.05
	Total Expense	3,997.70	3,926.80	3,217.86	7,144.66
V	Profit/(Loss) before exceptional items and Tax (III - IV)	2,958.72	1,767.98	1,266.17	3,034.15
VI	Exceptional Items Before Tax	-	-	-	-
VII	Exceptional Items (Net of Tax)		-	-	-
VIII	Profit Before Tax (V-VII)	2,958.72	1,767.98	1,266.17	3,034.15
	Tax expense		-		
	(1) Current tax	96.62	(34.28)	345.11	310.83
	(2) Deferred tax	27.81	(9.09)	18.22	9.13
	(3)Short/(Excess) provision of earlier year	-	-	1.01	1.01
IX	Total Tax Expense	124.43	(43.37)	364.34	320.97
X	Profit/(Loss) for the period from continuing operations (VIII-IX+VII)	2,834.29	1,811.35	901.83	2,713.18
XI	Profit/(Loss) from discontinued operations	-	-	-	-
XII	Tax expense of discontined operations	-	-	-	-
XIII	Profit/(Loss) from discontinued operations (after tax)(X-XI-XII)	-	-	-	-
XIV	Profit After tax for the period (X+XIII)	2,834.29	1,811.35	901.83	2,713.18
XV	Share in profit/(loss) of Associate	28.89	(5.93)	3.86	(2.07)
XVI	Profit for the Period	2,863.18	1,805.42	905.69	2,711.11
XVII	Other Comprehensive Income (OCI)				
	(A) Items that will not be reclassified to profit or loss				
	Remeasurement Loss on Defined benefit plans	(2.22)	(1.49)	(1.32)	(2.81)
	Income Tax effect on above	0.56	0.38	0.33	0.71
	B) Items that will be reclassified to profit or loss				
	Exchange Difference in translating the financial Statement of foreign operations	-	-	-	-
	Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
	Total Other Comprehensive Income /(Loss)	(1.66)	(1.11)	(0.99)	(2.10)
	Total profit including Comprehensive Income (XVI+XVII)	2,861.52	1,804.31	904.70	2,709.01
	Net Profit atttributable to:				
	Equity shareholders of the parent	1,510.83	900.74	517.48	1,413.22
	Non-controlling Interest	1,352.35	904.68	393.21	1,297.89
	Other Comprehensive Income attributable to:				
	Owners of the company	(1.66)	(1.11)	(0.99)	(2.10)
	Non-controlling Interest	-	-	-	-
	Total Comprehensive Income attributable to:	2,861.52	1,804.31	904.70	2,709.01
	Equity shareholders of the parent	1,509.17	899.63	511.49	1,411.12
	Non-controlling Interest	1,352.35	904.68	393.21	1,297.89
	Earnings per Equity Share (Rs.) : (Equity share of par value of Rs.10/- each)				
	Basic	9.80	5.85	3.32	9.17
	Diluted	9.79	5.85	3.32	9.17
	EPS for the half year ended are not annulaised				

NOTES :

1 This is the first period for which the Company has prepared financial results in compliance with Ind AS. Prior to April 1, 2025, the Company had prepared its Financial Statement in accordance with the Accounting Standards notified under 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP)

2 The Company has adopted Ind AS (Indian Accounting Standards) w.e.f April 1, 2025. The Reconciliation of Net Profit reported in accordance with Previous GAAP to total comprehensive Income in accordance with Ind AS for the year ended 30th September, 2024 as mentioned in point number 1 is given below.

Rs. In Lakhs

Particulars	Half-Year Ended on 30th September 2024 (Unaudited)	
	Consolidated	Standalone
Net Profit for the period under previous Indian GAAP	517.38	112.75
Adjustements on account of:		
Employee benefit expense	1.32	1.32
Interest Income	0.18	0.18
Interest expense on security deposit	(0.16)	(0.16)
Interest expense on lease	(5.54)	-
Rent expense	29.43	-
Depreciation	(25.02)	-
Tax	(8.39)	1.11
Conversion of JV to Subsidiary on account of IND AS	395.84	-
FCTR	(3.21)	
Net Profit for the period as per IND AS	901.83	115.20

3 The standalone/Consolidated financial results of the company have been prepared in, accordance with Indian Accounting standards (Ind AS) as prescribed under section 133 of the companies Act 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulation, 2015. The company has also reclassified the previous figures in accordance with the requirements applicable in the current period.

4 The Statutory Auditors have conducted Limited Review of the above mentioned half yearly financial results of September 30, 2025, as required by regulation 33 of SEBI (LODR) regulations, 2015.

5 Basic earnings per share are calculated by dividing the profit after Tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of 6 lakhs number of equity share warrants amouting to Rs.906 lakhs issued during the period for computing dilutive potential equity shares

6 The company has approved the allotement of 7 Lakhs convertible warrants at Rs. 151 per warrant in its extra ordinary general meeting held on April 9, 2025 and the subsequent in principle approval is granted by the NSE.The company has already converted 1 lakhs warrants into equity shares during the half year period ending on 30th September 2025. The balance 6 lakhs warrants are outstanding and the company has received the 25% of the issue price for such warrants.The warrants are convertible into equal number of equity share and the conversion option can be exercised at any time during the period of 18 months from the date of allotement of the said warrants.

7 The Statutory Auditors of the Company have carried out Limited Review of the financial results for the Year ended on September 30, 2025 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015. The above financial results have been audited and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 14th November, 2025.

8 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.

9 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.

10 There are no investors complaints pending as on 30 september, 2025.

11 The figures for half year ended 31st March, 2025 are the balancing figures between the unaudited IND AS numbers in respect of Financial Year 2024-25 and the published unaudited figures of the Half Year ended September 30, 2024, which were subject to limited review.

12 The name of the company has been changed from Unihealth Consultancy Limited to Unihealth Hospitals Limited vide MCA certificate of Incorporation dated 14th October, 2024.

13 The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30th , 2025 is as under:-

Object	Amount Utilized
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	281.44
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion*	237.50
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00
General Corporate Purpose	1093.08
Issue Expenses	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

For and on behalf of the Board of Directors
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place: Mumbai
Date: 14th November 2025

UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER 2025

(Rupees in lakhs)

Sr. No.	Particulars	As at 30-Sep-25 Unaudited	As at 31-Mar-25 Unaudited	As at 01-Apr-24 Unaudited
A.	**ASSETS**			
I	**Non-current assets**			
(a)	Property plant and equipment & Intangible Assets	5,271.69	5,332.72	5,230.56
(b)	Capital work in progress	982.02	529.02	74.96
(c)	Investment Property	-	-	-
(d)	Goodwill	891.42	891.42	891.42
(c)	Right-of-use assets	988.30	540.88	72.24
(c)	Financial assets			
(f)	Financial assets			
	Investments	47.71	18.82	20.90
	Other	387.64	296.79	152.93
(e)	Non-current Investments	-		-
(d)	Deferred tax assets	-		-
	Total non-current assets	**8,568.78**	**7,609.65**	**6,443.01**
II	**Current assets**			
(a)	Inventories	380.60	423.58	376.04
(b)	Financial assets			
	(i) Investments			-
	(ii) Trade receivables	11,225.30	8,215.62	5,391.18
	(iii) Cash and cash equivalents	849.17	836.38	1,329.22
	(iv) Bank Balance other than (iii) above	0.50	725.00	1,700.00
	(iv) Loans and advances	-	-	-
	(v) Other financial assets	14.21	17.31	13.18
(c)	Current Tax assets	113.50	-	-
(c)	Other current assets	954.63	710.29	63.13
	Total current assets	**13,337.91**	**10,928.18**	**8,872.75**
	Total assets	**22,106.69**	**18,537.83**	**15,315.76**
B	**EQUITY AND LIABILITIES**			
I	**Equity**			
(a)	Equity share capital	1,550.00	1,540.00	1,540.00
(b)	Other equity	10,984.90	8,596.15	7,107.79
(c)	Non controlling interest	5,397.55	4,045.21	2,536.00
	Total equity	**17,932.45**	**14,181.36**	**11,183.79**
II	**Non-current Liabilities**			
(a)	Financial liabilities			
	(i) Borrowings	665.96	538.65	1,760.85
	(ii) Lease liabilities	791.58	571.33	75.12
(b)	Provisions	28.95	26.15	25.85
(c)	Deferred Tax Liabilities	355.04	331.68	322.55
	Total non-current liabilities	**1,841.53**	**1,467.81**	**2,184.37**
III	**Current liabilities**			
(a)	Financial liabilities			
	(i) Borrowings	137.07	1,098.65	674.23
	(ii) Lease liabilities	165.23	11.19	-
	(iii) Trade payables			-
	Total outstanding dues of micro enterprises and small enterprises	98.97	11.44	0.28
	Total outstanding dues of creditors other than micro enterprises and small enterprises	692.90	582.24	449.65
	(iv) Other current financial liabilities	358.05	505.37	148.06
(b)	Other current liabilities	183.00	122.50	196.48
(c)	Provisions	697.49	557.27	478.90
	Total current liabilities	**2,332.71**	**2,888.66**	**1,947.60**
	Total Liabilities	4,174.24	4,356.47	4,131.97
	Total equity and liabilities	22,106.69	18,537.83	15,315.76
	Material Accounting Policies			
	The accompanying notes are an integral part of the Consolidated Financial Statements			

For and on behalf of the Board of Directors
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place: Mumbai
Date: 14th November 2025

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR PERIOD ENDED 30TH SEPTEMBER 2025

(Rupees in lakhs)

	Particulars	For the Year ended 30-Sept-2025 Unaudited	For the Year ended 31-Mar-2025 Unaudited
A.	**Cash flows from operating activities**		
	Profit/(loss) before tax	2,958.72	3,034.15
	Depreciation and amortisation expenses	-	-
	Interest Income	384.64	595.27
	Finance cost	(9.59)	(115.83)
	Unrealised foreign exchange (gain)/Loss	118.31	315.03
	Operating profit / (loss) before working capital changes	(524.48)	(8.86)
	Changes in working capital:	2,927.60	3,819.76
	Increase / (decrease) in trade payables		
	Increase / (Decrease) in other current liabilities	198.19	143.74
	Increase / (decrease) in provisions	60.50	(73.98)
	Increase / (decrease) in other current financial liabilities	143.02	75.85
	(Increase) / decrease in other financial assets and other current assets	(147.32)	357.31
	(Increase) / decrease in short term loan and advances	(332.09)	(795.14)
	(Increase) / Decrease in trade receivables	-	-
	(Increase) / decrease in inventories	(3,009.68)	(2,824.44)
	Net changes in working capital	42.98	(47.54)
	Cash flow from operating activities post working capital changes	(3,044.40)	(3,164.20)
	Less: Income taxes (paid)/refunded, net	(116.80)	655.56
	Net cash generated from / (used in) operating activities (A)	11.49	(311.84)
		(105.31)	343.73
B.	**Cash flows from investing activities**		
	Proceeds/(investments) in fixed deposits & shares (net)		
	Purchase of property, plant and equipment		
	Interest received	(939.67)	(1,619.96)
	(Increase)/Decrease in bank balances other than cash and cash equivalents	9.59	115.83
	Net cash generated from / (used in) investing activities (B)	724.50	975.00
		(205.58)	(529.13)
C.	**Cash flows from financing activities**		
	Proceeds from non current borrowings		
	Proceeds from current borrowings (net)	127.31	(1,222.19)
	Proceeds from issue of shares	(961.58)	424.42
	Proceeds from issue of Share Warrants	151.00	
	Finance Cost	226.50	-
	Payment of lease liabilities	(118.31)	(25.93)
	Net cash generated from / (used in) financing activities (C)	374.28	507.40
		(200.80)	(316.30)
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	(511.69)	(501.70)
	Cash and Cash equivalents at the beginning of the year	836.38	1,329.22
	Effect of foreign exchange gain/loss	524.48	8.86
	Cash and Cash equivalents at end of year	849.17	836.38

Material Accounting Policies (Refer Note No. 1)
The accompanying notes are an integral part of the Consolidated Financial Statements

Notes

(i) Cash flow statement has been prepared under the indirect method as set out in Ind AS - 7 specified under Section 133 of the Companies Act 2013.

For and on behalf of the Board of Directors
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place: Mumbai
Date: 14th November 2025

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)

UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES FOR THE HALF YEAR PERIOD ENDED 30TH SEPTEMBER 2025

(₹ in Lakhs)

Geographic Segment	30-09-2025	31-03-2025	30-09-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited
1. Segment Revenue				
India	898.86	702.05	510.06	1,212.11
Uganda	6,324.31	5,033.43	3,663.97	8,697.39
Tanzania	25.40	18.00	46.32	64.32
Nigeria	10.06	235.47	422.10	657.57
Mauritius	14.41	11.73	-	11.73
UAE	-	0.54	41.84	42.37
Total Segment Revenue	**7,273.04**	**6,001.21**	**4,684.29**	**10,685.49**
Less: Inter Segment Revenue	316.62	306.43	200.26	506.68
Total Segment Revenue from Operations	**6,956.42**	**5,694.78**	**4,484.03**	**10,178.81**
2. Segment Results (Profit Before Tax)				
India	191.65	45.12	183.39	228.47
Uganda	2,849.77	1,764.06	1,037.89	2,801.98
Tanzania	(42.05)	(35.46)	(23.36)	(58.81)
Nigeria	(47.90)	3.05	68.70	71.75
Mauritius	11.46	4.05	(17.39)	(13.34)
UAE	(4.21)	(12.84)	16.94	4.10
Total Segment Results	**2,958.72**	**1,767.98**	**1,266.17**	**3,034.15**
3. Segment Assets		-		
India	10,488.54	9,098.36	7,085.00	9,098.36
Uganda	15,410.19	12,600.62	9,818.85	12,600.62
Tanzania	573.34	416.04	364.58	416.04
Nigeria	622.90	639.03	609.56	639.03
Mauritius	443.15	418.02	419.28	418.02
UAE	757.02	728.02	747.25	728.02
Total Segment Assets	**28,295.14**	**23,900.09**	**19,044.52**	**23,900.09**
Less: Inter Segment Elimination	6,188.45	5,362.26	3,422.38	5,362.26
Total Assets	**22,106.69**	**18,537.83**	**15,622.14**	**18,537.83**
4. Segment Liabilities				
India	2,417.34	1,526.06	392.44	1,526.06
Uganda	4,656.06	5,128.99	4,237.86	5,128.99
Tanzania	726.85	591.45	497.06	591.45
Nigeria	345.21	316.54	346.27	316.54
Mauritius	1.51	4.21	16.50	4.21
UAE	5.50	1.22	21.96	1.22
Total Segment Liabilities	**8,152.47**	**7,568.47**	**5,512.09**	**7,568.47**
Less: Inter Segment Elimination	3,978.23	3,212.00	1,926.02	3,212.00
Total Liabilities	**4,174.24**	**4,356.47**	**3,586.07**	**4,356.47**

For and on behalf of the Board of Directors
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place: Mumbai
Date: 14th November 2025